# AZD8421

Source: https://onco.cc/drugs/azd8421/  
OnCo record `azd8421` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD8421 is a small-molecule inhibitor from AstraZeneca, in registered phase 2 trials for ovarian cancer.

## Summary

AZD8421 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by AstraZeneca, in ovarian cancer. Described in the registry record as a cdk2 inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: AZD8421
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a cdk2 inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of AZD8421: https://clinicaltrials.gov/search?intr=AZD8421

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ](https://onco.cc/trials/nct06188520/)

---
JSON: https://onco.cc/api/v1/entities/azd8421.json